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OBJECTIVE: To investigate the effect of obstructive sleep apnea and continuous positive airway pressure
treatment on serum butyrylcholinesterase activity and ischemia-modified albumin levels.
METHODS: Thirty-two patients with obstructive sleep apnea and 30 age- and sex-matched controls were
enrolled and underwent a diagnostic polysomnogram. The serum butyrylcholinesterase activity, ischemia-
modified albumin levels, metabolic parameters, and polysomnography scores were detected and evaluated.
Nine patients were studied before and after treatment with continuous positive airway pressure.
RESULTS: The serum ischemia-modified albumin levels were significantly higher and the butyrylcholinesterase
activity was significantly lower in patients with obstructive sleep apnea than in the controls (p,0.001). The
continuous positive airway pressure treatment decreased the modified albumin levels and elevated the
buthrylcholinesterase activity (p=0.019 and p=0.023, respectively). The modified albumin levels were positively
correlated with the apnea-hypopnea index (r=0.462, p=0.008) at baseline. Elevated ischemia-modified
albumin levels can be more accurate than butyrylcholinesterase activity at reflecting the presence of obstructive
sleep apnea. Receiver operating characteristic curves revealed a significant difference between the areas under
the curve 0.916 for ischemia-modified albumin and 0.777 for butyrylcholinesterase (z=2.154, p=0.031).
CONCLUSION: The elevated ischemia-modified albumin level was significantly associated with obstructive sleep
apnea and was more sensitive than butyrylcholinesterase activity in reflecting obstructive sleep apnea. The
continuous positive airway pressure treatment helped to ameliorate the imbalance.
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& INTRODUCTION
Obstructive sleep apnea (OSA) is a common disorder
characterized by recurrent obstructions of the upper airways
associated with snoring, disrupted sleep and intermittent
hypoxia. OSA is frequently associated with several symp-
toms including excessive daytime somnolence, fatigue,
reduced quality of life as well as increased risk of
cardiovascular disease (1,2). Previous studies have shown
that OSA is associated with increased levels of inflammatory
mediators (3) and oxidative stress (2,4). Increased oxidative
stress is secondary to the process of repeated oxygen
desaturation and resaturation. Nasal continuous positive
airway pressure (nCPAP) is an effective therapy for reducing
apnea-related hypoxia and the levels of oxidative stress and
pro-inflammatory factors (5-7).
Butyrylcholinesterase (BChE) is present in the serum and
is synthesized by the liver (8). BChE may have a role in a
number of metabolic functions and could affect the
expression of insulin resistance and type 2 diabetes.
Butyrylcholinesterase may be a predictor of diabetes and
may reduce oxidative stress in diabetic patients (9,10). The
levels of butyrylcholinesterase activity could serve as a
marker of low-grade systemic inflammation in some clinical
conditions (11). To our knowledge, the influence of OSA on
butyrylcholinesterase activity is poorly understood.
Elevated ischemia-modified albumin (IMA) levels have
been demonstrated in patients with various diseases (12,13)
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and been advocated as a non-specific risk marker for
evaluating the oxidative stress status or atherosclerotic
burden (14,15). The oxidative balance is impaired in patients
with OSA, leading to the increased production of free
radicals and pro-inflammatory cytokines. Such imbalances
are the root of oxidative damage at the cellular and sub-
cellular levels (2). Although the potential roles for serum
butyrylcholinesterase activity and modified albumin levels
are well established in clinical disorders except OSA, the
influence of apnea-related hypoxia on the two markers
remains unclear. To the best of our knowledge, no studies
have investigated this topic. This prospective study was
designed to evaluate the potential role of the two markers in
OSA patients. We aimed to observe the effect of nCPAP
treatment on serum butyrylcholinesterase activity and
ischemia-modified albumin levels.
& METHODS
Patients and Study Design
This controlled study was performed at the pulmonary
medicine center of two medical college-affiliated hospitals
from January 2011 to January 2012. The participants were
selected from consecutive subjects who were seen at the sleep
unit and fulfilled the study inclusion criteria. Non-smoking
subjects aged 25-65 who were suspected of OSA were screened
and underwent a diagnostic polysomnogram. All of the
participants underwent overnight polysomnography at the
sleep unit. The studies were performed with a computerized
system (Somno-ScreenTM, SomnoMedics, Randersacker,
Germany). The test began at 11:30 PM and finished at 7:00
AM. An electroencephalogram registered with two channels
(C4/A1 and C3/A2), an electroculogram, a submental and
tibial electromyogram and airflow by pressure signal were
conducted. Snoring, thoracic and abdominal effort, electrocar-
diographic derivation (V2) and SaO2 by digital pulse oximetry
were monitored. Manual scoring of each polysomnography
was set, and the criteria for OSA and the polysomnography
technique were previously developed (16,17).
The apnea-hypopnea index (AHI) is the total number of
apneas and hypopneas per hour of actual sleep time. OSA
was defined as AHI$5 events per hour of sleep. The
OSA was graded as follows: mild, 5#AHI,20; moderate,
20#AHI,40; and severe, AHI$40 (16). The oxygen desa-
turation index was defined as the total number of dips in
SpO2$4% per hour of sleep. The lowest SpO2 (%) was
calculated and recorded.
All of the subjects underwent a physical examination,
including a review of the clinical records, systolic and
diastolic blood pressure, and body mass index (BMI). After
a 10-hour fast, blood samples were drawn at 7:30 AM to 8:00
AM from the subjects by venipuncture into Vacutainer
tubes. An electrocardiogram and digital chest radiography
were performed.
Continuous Positive Airway Pressure
The OSA patients were recommended for a four-week
nasal CPAP treatment, as needed. The nCPAP treatment
was performed with a specific instrument (ResMed,
Abingdon, UK) on the nine OSA patients. The most optimal
treatment pressure for each OSA patient was established
during the first night of nCPAP treatment, followed by four
weeks of successive nCPAP treatment during sleep. The
treatment lasted 6-8 hours per night with pressure levels
ranging from 7.6-15.6 cm H2O (18). Samples of peripheral
venous blood were collected as described above before the
initiation of therapy and four weeks after the administration
of treatment.
The controls that did not exhibit clinical evidence of a
major disease underwent a routine medical check-up. The
patients suffering from acute alcohol intoxication, chronic
renal failure, congestive heart failure, inflammatory condi-
tions, or ischemic events were excluded from the study.
Thirty age-, gender-, and BMI-matched controls screened
from ninety-three non-smoking subjects and thirty-two OSA
patients participated in the study.
Biochemical Assays
After an overnight fast, blood samples were drawn by
venipuncture into Vacutainer tubes. The serum ischemia-
modified albumin levels were measured using a commercially
available kit (Co-Health (Beijing) Laboratories Co., Ltd.,
Beijing, China) on an Olympus AU 2700 autoanalyzer
(Olympus, Tokyo, Japan). The serum butyrylcholinesterase
activity was measured on the identical autoanalyzer with a
commercially available kit (Whitman (Nanjing) Biotech Co.,
Ltd, Nanjing, China). The intra-assay variability for ischemia-
modified albumin and butyrylcholinesterase was below 4.0%.
The glycated hemoglobin A1c (HbA1c) levels were measured
using an HbA1c Meter from Bio-Rad Laboratories, Ltd.
(Shanghai, China). Blood tests, including cardiac enzymes,
fasting plasma glucose, lipid profiles, and routine biochemical
detection, were performed for all of the participants.
Statistical Analyses
The quantitative data are presented as the mean ¡
standard deviation. The statistical analyses were conducted
with the SPSS 18.0 package for Windows (SPSS Inc.,
Chicago, IL). A comparative analysis between the two
groups was carried out using Student’s t-test. Chi-squared
tests were utilized for the comparison of other clinical
features. Paired Student’s t-tests were utilized to determine
the significance of the changes in the OSA cases before and
after the nCPAP treatment. The correlations between the
variables were examined by Pearson’s correlation test and a
multiple linear regression analysis. The risk markers for
OSA were examined by multiple logistic analyses. To
determine the diagnostic performance of the variables, a
receiver operating characteristic (ROC) curve analysis was
performed using MedCalcH version 12.1.4.0. A two-tailed
p-value ,0.05 was considered statistically significant.
Ethical Issues
The study was approved by the ethics committee of
Xuzhou Medical College. The study was carried out in
accordance with the principles of the Declaration of Helsinki
as revised in 2001. Upon acceptance into the study, written
informed consent was obtained from the participants.
& RESULTS
Clinical Characteristics
The baseline demographic and clinical characteristics of
the subjects are shown in Table 1. A total of 62 subjects,
including 32 OSA patients, were included in the study. Four
moderate and five severe OSA patients received nCPAP
treatment for four weeks. The blood pressure, lipid profiles,
HbA1c, and plasma glucose levels were significantly higher
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in the OSA group than in the control group (all p,0.05). The
differences in the percentage of diabetes, dyslipidemia, and
hypertension presentation between the OSA and control
group did not reach statistical significance. There were no
significant differences in the age, gender, or body mass
index between the two groups.
Eighteen patients presented with severe OSA, 12 patients
exhibited moderate OSA, and 2 patients had mild OSA. The
clinical and laboratory characteristics observed before the
initiation of treatment were grouped according to the
severity of AHI, and the oxygen desaturation index is
shown in Table 2. The body mass index, blood pressure, and
polysomnography parameters were significantly different
in the severe OSA patients compared with the mild/
moderate OSA patients (all p,0.05). There was a significant
difference in the ischemia-modified albumin levels between
the severe and the mild/moderate OSA cases (p = 0.015). No
difference was found in the serum butyrylcholinesterase
activity between the two groups (p= 0.311).
Serum Biomarkers Levels
The mean butyrylcholinesterase activity was lower in the
OSA group than in the control group (p,0.001). The serum
modified albumin levels were significantly higher in the OSA
group compared with the control group (p,0.001). The
butyrylcholinesterase activity and modified albumin levels were
significantly altered in the nine OSA patients after nCPAP
treatment (final mean concentrations of 54.56¡7.50 U/L and
7403.44¡1077.98 U/L, respectively) compared with the bio-
marker concentrations observed upon admission (p= 0.019 and
p= 0.023, respectively). The alterations are shown in Figure 1.
The lipid levels and blood pressure were reduced to varying
degrees after nCPAP treatment as shown in Table 3.
Correlation and Regression Analyses
Bivariate correlation analyses were performed to assess
the relationships between the baseline serum butyrylcholi-
nesterase activity and the ischemia-modified albumin
Table 1 - Clinical and biochemical characteristics of the study participants.
Variables Controls (n = 30) OSA (n =32) p-value
Female/Male (n/n) 9/21 10/22 0.220
Age (years) 40¡12 40¡11 0.320
Body mass index (kg/m2) 28.63¡3.10 28.10¡5.52 0.768
Systolic blood pressure (mmHg) 123¡15 137¡22 0.021
Diastolic blood pressure (mmHg) 71¡10 84¡17 0.022
Apnea-hypopnea index (events/h) 3.06¡1.01 46.68¡22.45 ,0.001
Oxygen desaturation index (events/h) 1.66¡0.31 40.20¡15.76 ,0.001
Lowest SpO2 (%) 87.70¡12.00 77.07¡11.93 ,0.001
SpO2 , 90% (%TST) 2.34¡0.22 11.35¡6.87 ,0.001
Fasting plasma glucose (mmol/L) 4.50¡0.35 6.58¡2.20 0.002
Glycated hemoglobin A1c (%) 4.69¡1.03 6.67¡1.74 0.031
Total cholesterol (mmol/L) 4.72¡0.72 6.03¡0.91 0.023
Triglycerides (mmol/L) 1.72¡0.71 3.21¡1.31 0.022
High-density lipoprotein cholesterol (mmol/L) 1.34¡0.40 1.04¡0.26 0.327
Low-density lipoprotein cholesterol (mmol/L) 2.86¡0.37 3.19¡1.52 0.034
Butyrylcholinesterase (U/L) 9506¡1500 7430¡2051 ,0.001
Ischemia-modified albumin (U/L) 47.50¡9.16 65.10¡9.84 ,0.001
Diabetes mellitus (%) 5 (16.67) 7 (21.88) 0.220
Dyslipidemia (%) 10 (33.33) 13 (40.63) 0.170
Hypertension (%) 8 (26.67) 11 (34.34) 0.180
Therapy
Oral anti-diabetic therapy (%) 5 (16.67) 7 (21.88) 0.220
Oral anti- hypertension therapy (%) 7 (23.33) 10 (31.25) 1.000
Statin 2 (6.67) 3 (9.38) 0.531
All of the values in the table are given as the mean ¡ standard deviation.
Table 2 - Demographic information and laboratory values for obstructive sleep apnea patients at admission (n=32).
Variable OSA p-value
Mild/Moderate OSA Severe OSA
Female/Male (n/n) 5/9 5/13 0.270
Age (years) 48¡19 45¡14 0.612
Body mass index (Kg/m2) 25.82¡3.50 30.30¡6.53 0.023
Systolic blood pressure (mmHg) 135¡15 151¡17 0.039
Diastolic blood pressure (mmHg) 84¡7 99¡6 0.031
Apnea-hypopnea index (events/h) 25.26¡7.18 63.34.87¡14.42 ,0.001
Lowest SpO2 (%) 85.09¡6.27 71.88¡11.96 ,0.001
SpO2 , 90% (%TST) 9.76¡4.55 15.09¡8.09 0.004
Butyrylcholinesterase (U/L) 7854¡2272 7101¡1861 0.311
Ischemia-modified albumin (U/L) 60.43¡6.47 68.74¡10.61 0.015
All of the values in the table are given as the mean ¡ standard deviation.
IMA and BChE in OSA
Yang LX et al.
CLINICS 2013;68(7):968-973
970
concentrations and metabolic parameters in the OSA
patients. As shown in Figure 2, the serum modified albumin
level was positively correlated with AHI (r= 0.462, p= 0.008)
and was not correlated with other variables in the OSA
patients. The correlations between butyrylcholinesterase
and ischemia-modified albumin, AHI and other metabolic
parameters reached no difference.
In the correlation test, there was no other variable with a
p-value ,0.1. Only AHI was an independent factor
influencing the baseline modified albumin levels. To
determine which variable was independently associated
with OSA, multiple logistic regression analyses were
performed with the two significant clinical markers (butyr-
ylcholinesterase and ischemia-modified albumin). The odds
ratios (ORs) and 95% confidence intervals (CIs) were
calculated (OR= 1.000, p= 0.067, 95% CI: 0.999-1.004; and
OR= 1.195, p= 0.001, 95% CI: 1.077-1.326 for butyrylcholi-
nesterase and ischemia-modified albumin, respectively).
ROC Analyses
As shown in Figure 3, an ROC analysis was used to
identify the optimal serum ischemia-modified albumin level
and butyrylcholinesterase activity cutoff values for reflect-
ing OSA. The optimal diagnostic cutoff that maximally
increased the sensitivity and specificity in the estimation of
OSA was 54.00 U/L for ischemia-modified albumin (for a
sensitivity and specificity of 90.6% and 83.3%, respectively).
For the butyrylcholinesterase activity, this point was
calculated as 7890.08 U/L (for a sensitivity and specificity
of 59.4% and 93.3%, respectively). We observed significant
differences between the AUCs for the modified albumin
(0.916¡0.038) and butyrylcholinesterase (0.777¡0.059)
(z= 2.154, p= 0.031). Compared to the butyrylcholinesterase
activity, the modified albumin levels had a higher diag-
nostic value.
& DISCUSSION
The potential role of ischemia-modified albumin in
ischemic and non-ischemic diseases has been confirmed in
previous studies (11-15). The higher modified albumin
levels observed in non-ischemic disease patients confirms
that it may be of non-cardiac origin and reflect oxidative
stress and systemic inflammation (13-15). In this study, the
serum butyrylcholinesterase activity and ischemia-modified
Figure 1 - Changes in the serum butyrylcholinesterase activity
and ischemia-modified albumin levels in nine obstructive sleep
apnea patients at baseline and after treatment with continuous
positive airway pressure.
Table 3 - Demographic information and laboratory values for obstructive sleep apnea patients at baseline and after
nasal continuous positive airway pressure treatment (n= 9).
Variable Baseline CPAP p-value
Female/Male (n/n) 1/8 1/8 /
Age (years) 55¡4 / /
Body mass index (Kg/m2) 28.56¡1.92 28.10¡1.12 0.563
Systolic blood pressure (mmHg) 140¡6 135¡8 0.120
Diastolic blood pressure (mmHg) 93¡9 83¡4 0.035
Apnea-hypopnea index (events/h) 51.5¡29.0 N/A N/A
Fasting plasma glucose (mmol/L) 6.73¡0.67 5.80¡0.38 0.045
Total cholesterol (mmol/L) 4.12¡1.06 4.02¡0.68 0.215
Triglycerides (mmol/L) 1.65¡0.55 1.52¡0.61 0.034
High-density lipoprotein cholesterol (mmol/L) 1.34¡0.19 1.53¡0.42 0.531
Low-density lipoprotein cholesterol (mmol/L) 2.43¡0.86 2.20¡0.16 0.087
Butyrylcholinesterase (U/L) 6788¡1537 7403¡1077 0.023
Ischemia-modified albumin (U/L) 61.33¡8.77 54.56¡7.52 0.019
All of the values in the table are given as the mean ¡ standard deviation.
Figure 2 - The serum ischemia-modified albumin levels positively
correlated with apnea-hypopnea index (r=0.462, p=0.008) in
the obstructive sleep apnea patients.
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albumin levels were significantly different between the OSA
patients and the non-OSA controls. Treatment with nCPAP
had a favorable effect on the patient’s hypoxia and the two
biomarkers (butyrylcholinesterase and ischemia-modified
albumin). The elevated modified albumin levels were more
sensitive than butyrylcholinesterase activity at reflecting
OSA. Our results indicated that the modified albumin may
act as a valuable oxidative stress biomarker for OSA.
Butyrylcholinesterase has been shown to be elevated in
obesity, hypertension, dyslipidemia, diabetes and metabolic
syndrome (9-11). These cardiovascular risk factors are
commonly found in OSA patients. One could predict that
butyrylcholinesterase would be higher among the OSA
patients. The findings of this study showed the contrary.
The apnea-related hypoxia is a significant characteristic for
OSA patients. The hypoxia would be an inhibition factor of
liver function for this apparent paradox. This investigation
provided reliable information to explore the unknown
relationship.
Previous research indicates that OSA is associated with
increased cardiovascular morbidity and mortality (1). While
the underlying mechanisms are not entirely understood,
release of pro-inflammatory factors and increased oxidative
stress are commonly cited (18). The repeated apnea-related
hypoxic events in OSA initiate oxidative stress. A limited
number of studies have directly substantiated this hypothesis
by demonstrating increased free radical production in the
OSA leukocytes and increased plasma lipid peroxidation
(17). A previous study investigated a variety of oxidative
stress biomarkers, such as malondialdehyde (17) and soluble
receptors for the advanced glycation end-products (19) in
OSA. The indices of sleep apnea severity, the apnea-
hypopnea index and minimum oxygen saturation, were
independently associated with increased levels of triglycer-
ides, glucose, the cholesterol/HDL ratio, uric acid and C-
reactive protein (20), which is correlated with decreased
oxygen perfusion in the capillary vessels. An elevation in the
reactive oxygen species level triggers albumin modification.
Modification of the N-terminal peptide of human albumin
inhibits the ability of cobalt to bind to the protein. The
elevated ischemia-modified albumin levels in the OSA
patients may indicate increased oxidative stress but the
reduced butyrylcholinesterase activity reveals the hydrolysis
of oxidants and antioxidant depletion.
The majority of the patients in this study exhibited
moderate and severe obstructive sleep apnea syndrome.
The severe OSA patients were characterized by higher levels
of the apnea-hypopnea index, cardiovascular risk factors,
and ischemia-modified albumin. The serum modified
albumin levels were positively correlated with the apnea-
hypopnea index, suggesting a correlation between the
modified albumin levels and the severity of OSA. The
logistic regression and ROC analysis showed that modified
albumin levels may be a more suitable risk marker than
butyrylcholinesterase for reflecting the presence of OSA.
These results were in accord with the biomarkers’ potential
role. The levels of butyrylcholinesterase activity reached no
difference between the severe and the mild/moderate OSA
cases. The modified albumin had the ability to distinguish
the OSA severity.
It is hypothesized that there are other biological mechan-
isms involved in cellular dysfunction, including reduced
antioxidant capacity, inflammation, and cellular apoptosis,
which are activated during sleep apnea (18). Circulating
butyrylcholinesterase volatility was significantly correlated
with cardiovascular risk factors and antioxidant activity in
another direction (9,10). The serum butyrylcholinesterase
activity has previously been associated with insulin resis-
tance, type 2 diabetes, and BMI (8,21,22). We presented the
first data showing the alteration of serum butyrylcholines-
terase activity in OSA. The results from our study provided
further evidence for the imbalance of oxidation-antioxida-
tion in OSA. This study indicated a close relationship
between OSA-linked biomolecules and tissue dysfunction.
OSA is characterized by varying degrees of hypoxia. The
nCPAP treatment had a beneficial effect on the cardiovas-
cular risk factors and oxidative stress markers and increased
the serum butyrylcholinesterase activity of the nine OSA
patients while decreasing their modified albumin levels.
Previous studies demonstrated that the use of CPAP to treat
OSA in elderly patients reduced oxidative stress and
improved the quality of life (6,23). It is important to develop
a therapy that could prevent the development of cardiovas-
cular disease in OSA.
There are some limitations in our study. First, the results
represent preliminary evidence from a small study, and the
low number of mild OSA participants would not allow for
statistical calculation. Second, the altered modified albumin
levels and butyrylcholinesterase activity are common
observations in various illnesses, and the value of utilizing
this phenomenon in diagnosing OSA is very limited because
OSA has a well-established diagnostic criterion. Though our
results cannot replace the traditional diagnostic criterion,
this study adds complementary laboratory data and the
alteration patterns of both biomarkers. Future studies are
necessary to elucidate whether the modified albumin levels
could be utilized in monitoring varying degrees of OSA.
This study confirmed the changes of the serum modified
albumin levels and butyrylcholinesterase activity in
OSA patients. It was demonstrated that the serum
Figure 3 - The ROC plots show the significant difference between
the AUCs for butyrylcholinesterase activity (0.777 ¡ 0.059) and
ischemia-modified albumin (0.916 ¡ 0.038) (z=2.154, p=0.031)
in their ability to reflect obstructive sleep apnea. The optimal
diagnostic cut-off for the modified albumin was 70.75 U/L (for a
sensitivity and specificity of 84.4% and 83.3%, respectively). For
butyrylcholinesterase activity, this point was 7890.08 U/L (for a
sensitivity and specificity of 59.4% and 93.3%, respectively).
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ischemia-modified albumin levels could act as a better
biomarker than butyrylcholinesterase activity for reflecting
the presence of OSA.
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